298 related articles for article (PubMed ID: 37035397)
1. Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies.
Munir F; He J; Connors J; Garcia M; Gibson A; McCall D; Nunez C; Dinh CN; Robusto L; Roth M; Khazal S; Tewari P; Cuglievan B
Transl Pediatr; 2023 Mar; 12(3):487-502. PubMed ID: 37035397
[TBL] [Abstract][Full Text] [Related]
2. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
3. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives.
Lv M; Liu Y; Liu W; Xing Y; Zhang S
Front Immunol; 2022; 13():921894. PubMed ID: 35769486
[TBL] [Abstract][Full Text] [Related]
6. Current status of CAR-T cell therapy for pediatric hematologic malignancies.
Hiramatsu H
Int J Clin Oncol; 2023 Jun; 28(6):729-735. PubMed ID: 37154980
[TBL] [Abstract][Full Text] [Related]
7. Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study.
Wang S; Liu A; Wang N; Wang Y; Zhang A; Wang L; Yu W; Li C; Zhang Y; Hu Q
Front Pediatr; 2022; 10():1100404. PubMed ID: 36727001
[TBL] [Abstract][Full Text] [Related]
8. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
9. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
10. T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development.
Thomas X
Expert Opin Investig Drugs; 2023 Jan; 32(1):37-52. PubMed ID: 36541671
[TBL] [Abstract][Full Text] [Related]
11. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia.
Cuglievan B; McCall D; Robusto L; Mireles ME; Gettys SC
Expert Opin Pharmacother; 2022 Dec; 23(17):1915-1925. PubMed ID: 36346029
[TBL] [Abstract][Full Text] [Related]
13. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
14. Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia.
Tardif M; Souza A; Krajinovic M; Bittencourt H; Tran TH
Expert Opin Pharmacother; 2021 Oct; 22(14):1871-1887. PubMed ID: 34011251
[No Abstract] [Full Text] [Related]
15. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
16. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
Gavralidis A; Brunner AM
Curr Hematol Malig Rep; 2020 Aug; 15(4):294-304. PubMed ID: 32445026
[TBL] [Abstract][Full Text] [Related]
17. Novel therapy for childhood acute lymphoblastic leukemia.
Santiago R; Vairy S; Sinnett D; Krajinovic M; Bittencourt H
Expert Opin Pharmacother; 2017 Aug; 18(11):1081-1099. PubMed ID: 28608730
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia.
Malczewska M; Kośmider K; Bednarz K; Ostapińska K; Lejman M; Zawitkowska J
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454927
[TBL] [Abstract][Full Text] [Related]
19. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
